The WACC of Translate Bio Inc (TBIO) is 11.0%.
Range | Selected | |
Cost of equity | 69.80% - 152.00% | 110.90% |
Tax rate | -% - -% | -% |
Cost of debt | 7.00% - 11.80% | 9.40% |
WACC | 8.0% - 14.1% | 11.0% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 14.34 | 26.27 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 69.80% | 152.00% |
Tax rate | -% | -% |
Debt/Equity ratio | 62.26 | 62.26 |
Cost of debt | 7.00% | 11.80% |
After-tax WACC | 8.0% | 14.1% |
Selected WACC | 11.0% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for TBIO:
cost_of_equity (110.90%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (14.34) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.